Straits Times Index
3,316.56 -6.06 (-0.18%) Nikkei
38,646.11 -457.11 (-1.17%) Hang Seng
18,608.94 -259.77 (-1.38%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,639.36 +1,682.61 (+2.51%) CMC Crypto 200
1,440.81 -27.29 (-1.86%)
AUPH Jul 2024 8.000 put
| Previous close | 2.8500 |
| Open | 2.8500 |
| Bid | 2.6500 |
| Ask | 3.1000 |
| Strike | 8.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.8500 - 2.8500 |
| Contract range | N/A |
| Volume | |
| Open interest | 12 |
Business WireAnalysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 14, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced the presentation of results from an updated cost-effective analysis of LUPKYNIS (voclosporin), a second generation calcineurin inhibitor (CNI), at the annual National Kidney Foundation (NKF) Spring Clinical Meeting 2024 taking place in Long Beach, CA, May 14-18. The Company will also share additional data from its AURORA clinical program.
Business WireAurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ROCKVILLE, Md. & EDMONTON, Alberta, May 09, 2024--Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024
ZacksHow Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
The average of price targets set by Wall Street analysts indicates a potential upside of 96.5% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
